Biomednewsbreaks - VERAXA Biotech AG And Voyager Acquisition Corp. (NASDAQ: VACH,“Voyager”) Announce $1.64 Billion Business Combination To Create Clinical-Stage Cancer Therapy Powerhouse

(MENAFN- Investor Brand Network) VERAXA Biotech AG , a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH) announced a definitive agreement to merge in a transaction that would value the combined company at approximately $1.64 billion. Upon closing, VERAXA is expected to trade on NASDAQ under the ticker symbol“VERX.” The company is advancing a proprietary Bi-Targeted Antibody Cytotoxicity (“BiTAC”) platform for dual-marker cancer therapeutics, including bispecific ADCs and T cell engagers, with a pipeline featuring nine programs and an active Phase 1 trial in leukemia. VERAXA is backed by majority shareholders Xlife Sciences AG (SIX: XLS), EMBL and EMBLEM, and led by CEO Christoph Antz, Ph.D., and CBO Heinz Schwer, Ph.D., MBA. Voyager expects to provide up to $253 million in cash from its trust account to fund operations, while VERAXA is pursuing a crossover round expected to close before the deal's completion, targeted for Q4 2025.

To view the full press release, visit

About VERAXA Biotech

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTACTM formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technologies.

For more information, please visit .

On April 22, 2025, VERAXA entered into a definitive business combination agreement (the“Business Combination Agreement”) with Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH,“Voyager”). Upon closing of the Business Combination Agreement, VERAXA is expected to become a publicly traded company listed on NASDAQ. The Company has retained Anne Martina Group as the M&A advisor on the transaction.

About Voyager Acquisition Corp.

Voyager is a special purpose acquisition company with a bold mission: to revolutionize the healthcare sector through a merger, stock purchase, or business combination. Our team of experienced executives includes unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections. With these strengths, we not only seek to drive success but commit to scaling companies to unprecedented heights in the healthcare industry.

For more information, please visit .

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

MENAFN10062025000224011066ID1109658703